Orthobiologics in the Knee: Evidence Based Approach

Description

In a recent presentation, Iain Murray discusses the responsible use of orthobiologics, particularly in the context of knee treatments, and their implications in sports medicine and trauma. He emphasizes the importance of scientifically backed treatments and the controversy surrounding the irresponsible application of biologics. Murray highlights that orthobiologics, including treatments derived from human sources like PRP (Platelet-Rich Plasma), have grown into a lucrative industry, but their clinical effectiveness remains uncertain in many cases.



Murray plans to illustrate his points with two specific examples: ACL (anterior cruciate ligament) injuries and post-traumatic arthritis. He notes the importance of understanding different types of PRP and cell-based therapies, which are increasingly utilized to treat musculoskeletal conditions. The discussion also touches upon the challenges patients face due to misleading marketing and misinformation from medical providers regarding what these treatments entail.



Through his exploration of available evidence, Murray stresses the necessity of adhering to established clinical guidelines and evidence-based practices before considering experimental therapies. He points out the overwhelming number of randomized controlled trials related to ACL injuries and acknowledges the inadequacies in reporting standards for biologic treatments, which sometimes lead to ambiguous conclusions.



The talk raises critical questions about treatment efficacy and the actual mechanisms by which orthobiologic treatments operate, as exemplified by the interaction of certain cytokines within the body. Murray concludes by highlighting the need for transparency with patients, advocating for rigorous clinical research that considers the vast heterogeneity of osteoarthritis phenotypes and leads to better standardization in medical practices.

DOI: 10.1302/3114-230463

Specialties